These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 9422046)
1. Anagrelide for essential thrombocythemia. Med Lett Drugs Ther; 1997 Dec; 39(1016):120. PubMed ID: 9422046 [No Abstract] [Full Text] [Related]
2. Role of anagrelide in the treatment of thrombocytosis. Brooks WG; Stanley DD; Goode JV Ann Pharmacother; 1999 Oct; 33(10):1116-8, 1121. PubMed ID: 10534225 [TBL] [Abstract][Full Text] [Related]
3. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214 [TBL] [Abstract][Full Text] [Related]
4. Treatment of essential thrombocythemia in childhood. Scherer S; Ferrari R; Rister M Pediatr Hematol Oncol; 2003; 20(5):361-5. PubMed ID: 12775533 [TBL] [Abstract][Full Text] [Related]
5. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR]. Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of essential thrombocythemia with anagrelide in a child. Hermann J; Fuchs D; Sauerbrey A; Hempel L; Zintl F Med Pediatr Oncol; 1998 Jun; 30(6):367-70; discussion 370-1. PubMed ID: 9589087 [No Abstract] [Full Text] [Related]
7. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Laguna MS; Kornblihtt LI; Marta RF; Michiels JJ; Molinas FC Clin Appl Thromb Hemost; 2000 Jul; 6(3):157-61. PubMed ID: 10898276 [TBL] [Abstract][Full Text] [Related]
8. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group. Am J Med; 1992 Jan; 92(1):69-76. PubMed ID: 1731512 [TBL] [Abstract][Full Text] [Related]
9. Anagrelide: a new drug for treating thrombocytosis. Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187 [TBL] [Abstract][Full Text] [Related]
10. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Mazzucconi MG; Redi R; Bernasconi S; Bizzoni L; Dragoni F; Latagliata R; Santoro C; Mandelli F Haematologica; 2004 Nov; 89(11):1306-13. PubMed ID: 15531452 [TBL] [Abstract][Full Text] [Related]
11. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients]. Burkhard R; Adam H; Widmer L; Honegger HP Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387 [TBL] [Abstract][Full Text] [Related]
12. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia. Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866 [No Abstract] [Full Text] [Related]
14. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355 [TBL] [Abstract][Full Text] [Related]
15. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France. Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ; Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452 [TBL] [Abstract][Full Text] [Related]
16. [The results of patients with essentials thrombocythemia and other myeloproliferation-related thrombocythemia--a report of patients treated with Thromboreductin]. Penka M; Schwarz J; Pavlík T; Indrák K; Doubek M; Dulícek P; Pospísilová D; Kissová J; Jonásová A; Jelínková P; Hlusí A; Schutzová M; Cerná O; Brychtová Y; Nováková L; Korístek Z; Segethová J; Vozobulová V; Hadacová I; Hochová I; Voglová J; Walterová L; Bodzásová C; Dusek L Vnitr Lek; 2009 Nov; 55(11):I-XII. PubMed ID: 20017445 [TBL] [Abstract][Full Text] [Related]
17. Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results. Mazzucconi MG; De Sanctis V; Chistolini A; Dragoni F; Mandelli F Haematologica; 1992; 77(4):315-7. PubMed ID: 1427441 [TBL] [Abstract][Full Text] [Related]
18. Thrombocytosis--report of a case. Thomas M; Pavithran K; Salil ; Somarajan A J Assoc Physicians India; 2000 Apr; 48(4):441-2. PubMed ID: 11273186 [TBL] [Abstract][Full Text] [Related]